Cfara 20 mg Injection 20 ml
₹15000*
₹12750*
MRP ₹15000
15% CB
₹2250 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Cfara 20 mg Injection 20 ml is an anti-cancer medicine used in pediatric patients aged 1 - 21 years for the treatment of acute lymphoblastic leukaemia, a blood cancer that primarily affects the blood and bone marrow. Cfara 20 mg Injection 20 ml is used in patients with relapsed or refractory acute lymphoblastic leukaemia (ALL) after receiving at least two prior therapies.
Cfara 20 mg Injection 20 ml contains Clofarabine as an active ingredient in the class of antimetabolites. It works by inhibiting the DNA polymerase enzyme responsible for DNA elongation, synthesis, and repair.
Cfara 20 mg Injection 20 ml may cause certain side effects, such as skin rash, fatigue, headache, decreased platelet count, nausea, vomiting, diarrhoea, fever, anxiety, flushing, and injection site reactions. These side effects do not require medical attention and gradually resolve over time. A trained oncologist will administer Cfara 20 mg Injection 20 ml. Do not self-administer.
Cfara 20 mg Injection 20 ml should be avoided if you are allergic to it or any other components present in it. It should be used with caution in patients with a pre-existing or history of liver/kidney disease, gastrointestinal disorders, skin problems, and bleeding disorders, as it may cause serious side effects or worsen such conditions. This medicine is known to cause embryo-fetal toxicity. It is not recommended for use in pregnancy or breastfeeding.
Cfara 20 mg Injection 20 ml contains Clofarabine, which is used in the treatment of acute lymphoblastic leukemia (ALL). It works by inhibiting the DNA polymerase enzyme that is responsible for DNA elongation, synthesis, and repair. In general, it inhibits the production of genetic material (DNA) in the cancer cells that are essential for cell growth, repair and multiplication. Thus, Cfara 20 mg Injection 20 ml stops the multiplication of abnormal cells, leads to the growth of cells in an unbalanced way and causes the death of cells.
Cfara 20 mg Injection 20 ml should be avoided if you are allergic to it or any other components present in it. Before receiving, if the child has/had any history of liver/kidney disease, gastrointestinal disorders, skin problems, and bleeding disorders, as it may cause serious side effects or worsen such conditions. This medicine is known to cause embryo-fetal toxicity. Hence, inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment. Breastfeeding should be discontinued in nursing mothers during the treatment. Cfara 20 mg Injection 20 ml is given in children above one year of age only if prescribed by the doctor. Cfara 20 mg Injection 20 ml may cause myelosuppression, QT prolongation, hepatotoxicity, renal toxicity, cerebral, gastrointestinal and pulmonary haemorrhage, Tumor Lysis syndrome, severe infections, Systemic Inflammatory Response Syndrome (SIRS), enterocolitis, and skin reactions in some patients. Hence, inform your doctor about your complete medical and medication history before receiving this medicine.
Drug-Drug Interactions: Cfara 20 mg Injection 20 ml may interact with immunosuppressants (adalimumab, infliximab, natalizumab), antiviral medicine (saquinavir, efavirenz), live vaccines, antipsychotics (haloperidol, droperidol, clozapine), etc.
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: Inform your doctor if you have kidney or liver disease, , diabetes, and skin disorders before receiving Cfara 20 mg Injection 20 ml.
Acute Lymphoblastic Leukemia (ALL): Leukemia, also known as blood cancer, is a cancer of blood cells or blood-forming tissues. It causes excessive production of immature white blood cells by the bone marrow and reduces the body’s ability to fight infections. There are different types of blood cancers. ALL is a type of blood cancer that primarily affects your blood and bone marrow. It mainly targets the white blood cells, which can interfere with your body’s ability to combat infections. Symptoms may include fever, weight loss, abnormal blood cell count, bruising, and loss of appetite.
Alcohol
Unsafe
Avoid consuming alcohol while on treatment with Cfara 20 mg Injection 20 ml as it may cause severe side effects.
Pregnancy
Unsafe
Cfara 20 mg Injection 20 ml is not recommended for use in pregnancy as it may cause embryo-fetal toxicity and harm your foetus. Hence, if you are under 21 and pregnant or planning pregnancy, inform your doctor before receiving Cfara 20 mg Injection 20 ml. You should not become pregnant while you are taking Cfara 20 mg Injection 20 ml. Using effective birth control methods while on treatment is suggested.
Breast Feeding
Unsafe
There are no data on the presence of clofarabine in human milk, its effects on breastfed children, or its impact on milk supply; due to the possibility of serious adverse events in breastfed children, including genotoxicity, patients are advised not to breastfeed during therapy and for at least two weeks following the final dosage.
Driving
Not applicable
Cfara 20 mg Injection 20 ml is administered to hospitalized patients.
Liver
Caution
Cfara 20 mg Injection 20 ml has not been studied in patients with liver impairment. However, inform your doctor if you have liver problems.
Kidney
Caution
If you have a history of kidney disease or have a pre-existing condition, notify your doctor before getting Cfara 20 mg Injection 20 ml. Based on your situation, your doctor may adjust the dose of this medication or prescribe a suitable alternative. Cfara 20 mg Injection 20 ml has the potential to cause renal toxicity, which presents as high creatinine levels and sudden renal failure. Monitor renal function and adjust or discontinue Clolar as needed.
Children
Safe if prescribed
Cfara 20 mg Injection 20 ml is recommended for children and adolescents below 21 years of age only if prescribed by the oncologist.
Country of origin
Manufacturer/Marketer address
Product Substitutes